Toxicities during therapy with high doses of methotrexate in children with acute lymphoblastic leukemia

Authors

  • Билјана (Biljana) Чонеска-Јованова (Choneska-Jovanova) Универзитетеска клиника за детски болести (University Clinic for children's diseases Skopje)
  • Ката (Kata) Мартинова (Martionva) Универзитетеска клиника за детски болести (University Clinic for children's diseases Skopje)
  • Соња (Sonja) Алабаковска (Alabakovska) Институт за медицинска и експериментална биохемија, Медицински Факултет, Универзитет Св. Кирил и Методиј Скопје (Institute of Medical and Experimental Biochemistry, Medical Faculty University Sts Ciril and Methodius Skopje)
  • Зорица (Zorica) Антевска Трајкова (Antevska Trajkova) Универзитетеска клиника за детски болести (University Clinic for children's diseases Skopje)
  • Костандина (Kostandina) Кузевска Манева (Kuzevska Maneva) Универзитетеска клиника за детски болести (University Clinic for children's diseases Skopje)
  • Светлана (Svetlana) Кочева (Kocheva) Универзитетеска клиника за детски болести (University Clinic for children's diseases Skopje)
  • Александра (Аleksandra) Јовановска (Jovanovska) Универзитетеска клиника за детски болести (University Clinic for children's diseases Skopje)

Keywords:

acute lymphoblastic leukemia, methotrexate, toxic effects

Abstract

Intensification of systemic chemotherapy with incinclusionof high doses methotrexate (MTX) has contributed to the improvement of event-free survival in children with acute lymphoblastic leukemia (ALL). Despite this benefit, this agent might cause serious toxicity, even life-treating events during treatment. Therefore, prediction, early detection and management of toxic effects during therapy with high doses of MTX is still a great challenge for every pediatric oncologist.

The aim of our study was to evaluate the incidence of toxic effects of chemotherapy with high doses of MTX (5 g/m^2) and to compare them with toxicity during application of lower doses of MTX (2 g/m^2).

Retrospective record review of 77 children with medium risk ALL was done. Patients were treated in the Department of hematology and oncology at the University children's hospital in Skopje. Forty-five of them were treated with 5 g/m^2 and 32 of them were treated with 2 g/m^2 (historic group). Toxicity was registered according to the protocol for acute toxicity, part of the ALL BFM 95 protocol.

Toxic effects were predominant in the group treated with higher doses of MTX. The  most significant toxic  effects were hepatotoxicity, oral mucositis and myelosuppression.  More  severe grade of hepatotoxicity and oral mucositis were present in the study group. In our study toxic  effects were more common in the study group due to application of higher doses of MTX.

Variations in toxicity between the patients of the study group are probably due  to the genetic differences in the drug absorption, their excretion and cellular transport. Current studies are dedicated on discovering genetic markers which will  be able  to predict the risk  of appearance of MTX toxicity.

Downloads

Download data is not yet available.

References

Poplack D. Acute lymphoblastic leukemia. Vo: Pizzo P,

Poplack D, Ed. Principles and practice of Pediatric oncology,

Lippincot, 1993: 431-483.

Schrappe M, Pieters R. Acute lymphoblastic leukemia.

Vo: Pinkerton R, Plowman P, Pieters R, Ed. Pediatric

oncology, Arnold, 2004, 230-254.

BFM study group, Treatment protocol ALL-BFM 95 for

children and adolescents with acute lymphoblastic leucaemia,

a cooperative multicentar trial of the German society

for pediatric hematology and oncology, updated English

version of the original protocol, Novembеr, 10, 1997.

Schrappe M, Reiter A, Zimmerman M, et al. Long term

results of four consecutive trials in childhood ALL performed

by ALL-BFM study group from 1981-1995. Leukemia

;14: 2205-22.

Schmiegelow K. Advances in individual prediction of

methotrexate toxicity a review. Br J Haematol 2009;

: 489-503.

Gauri K, Rupal S, Sarfraz A. Experience with high dose

methotrexate therapy in childhood acute lymphoblastic

leukemia in a tertiary care centre of a developing

country. Pediatr Blood Cancer 2012; 59:448-53.

Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs

GT. Comparison of pharmacokinetics and toxicity

after high-dose methotrexate treatments in children

with acute lymphoblastic leukemia. Anticancer drugs

; 24(2): 189-197.

Vagace HM, Marzal CC, Jimenez M et al. Methotrexat –

induced subacute neurotoxicity in a child with acute

lymphoblastic leukemia carrying genetic polymorfisms

related to folate homeostasis. Am J Hematol Oncol

; 86: 98–101.

Van Hasselt JGC, van Eijkelenburg NKA, Huitema ADR,

Schellens JHM, Schouten-van Meeteren AYN. Severe

skin toxicity in pediatric patient treated with voriconazole

and concomitant methotrexate. Antimicrobial

Agents Chemother 2013; 57(6): 2878-81.

Pietrzyk JJ, Bik-Multanowski M, Balwierz W. et al. Additional

genetic risk factor for death in children with

acute lymphoblastic leukemia: A common polymorphism

of the MTHFR Gene. Pediatr Blood Cancer

; 52:364-368.

Farrow AC, Buchanan GR, Zwiener RJ, Bowman

WP and Winick NJ. Serum aminotransferase elevation

during and following treatment of childhood acute

lymphoblastic leukemia. JCO 1997; 15 (4): 1560-66.

Evans W, Relling M, Rodman J et al. Conventional

Compared with Individualized Chemotherapy for Childhood

Acute Lymphoblastic Leukemia. N Engl J Med

; 338:499-505

De Rotte M.C.F.J, Den Boer E, Bulatovik Calasan M et

al: Personalized medicine of methotrexate therapy.

Ned Tijdschr Klin Chem Labgeneesk 2012; 37: 50-53.

Luisa Garre M, Relling M., Kalwinsky D. et al. Pharmacokinetiks

and toxicity of methotrexate in children

with Down syndrome and acute lymphocytic leukaemia.

J Pediatr. 1987; Volume 111(4): 606-12

Published

2017-07-01

How to Cite

1.
Чонеска-Јованова (Choneska-Jovanova) Билјана (Biljana), Мартинова (Martionva) Ката (Kata), Алабаковска (Alabakovska) Соња (Sonja), Антевска Трајкова (Antevska Trajkova) Зорица (Zorica), Кузевска Манева (Kuzevska Maneva) Костандина (Kostandina), Кочева (Kocheva) Светлана (Svetlana), et al. Toxicities during therapy with high doses of methotrexate in children with acute lymphoblastic leukemia. Arch Pub Health [Internet]. 2017 Jul. 1 [cited 2026 Nov. 21];7(1):28-34. Available from: https://journals.mk/index.php/aph/article/view/952

Most read articles by the same author(s)